▶ 調査レポート

化学療法薬誘発性肢端紅斑(手足症候群)治療の世界市場(~2026年)

• 英文タイトル:Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。化学療法薬誘発性肢端紅斑(手足症候群)治療の世界市場(~2026年) / Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Status and Forecast 2020-2026 / MRC2-11QY11343資料のイメージです。• レポートコード:MRC2-11QY11343
• 出版社/出版日:QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、92ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:ヘルスケア
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は化学療法薬誘発性肢端紅斑(手足症候群)治療のグローバル市場について調査・分析したレポートです。種類別(鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン(ビタミンB6)、その他)市場規模、用途別(薬局・ドラッグストア、病院薬局、オンラインドラッグストア)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別化学療法薬誘発性肢端紅斑(手足症候群)治療の競争状況、市場シェア
・世界の化学療法薬誘発性肢端紅斑(手足症候群)治療市場:種類別市場規模 2015年-2020年(鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン(ビタミンB6)、その他)
・世界の化学療法薬誘発性肢端紅斑(手足症候群)治療市場:種類別市場規模予測 2021年-2026年(鎮痛剤、抗炎症剤・抗浮腫剤、抗ヒスタミン剤、NSAID、経口/局所グルココルチコイド、ピリドキシン(ビタミンB6)、その他)
・世界の化学療法薬誘発性肢端紅斑(手足症候群)治療市場:用途別市場規模 2015年-2020年(薬局・ドラッグストア、病院薬局、オンラインドラッグストア)
・世界の化学療法薬誘発性肢端紅斑(手足症候群)治療市場:用途別市場規模予測 2021年-2026年(薬局・ドラッグストア、病院薬局、オンラインドラッグストア)
・北米の化学療法薬誘発性肢端紅斑(手足症候群)治療市場分析:米国、カナダ
・ヨーロッパの化学療法薬誘発性肢端紅斑(手足症候群)治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの化学療法薬誘発性肢端紅斑(手足症候群)治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の化学療法薬誘発性肢端紅斑(手足症候群)治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの化学療法薬誘発性肢端紅斑(手足症候群)治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Taro、Oceanside Pharmaceuticals、Pfizer、Novartis、A-S Medication Solutions、Preferred Pharmaceuticals、Syntex Pharmaceuticals、Valeant Canada、Technilab Pharma、Allergan
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.

Market Analysis and Insights: Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Scope and Market Size
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan

Market segment by Type, the product can be split into
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Market segment by Application, split into
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue
1.4 Market by Type
1.4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Analgesics
1.4.3 Anti-Inflammatory And Anti-Edematous Agents
1.4.4 Antihistaminic
1.4.5 NSAIDs
1.4.6 Oral/Topical Glucocorticoids
1.4.7 Pyridoxine (Vitamin B6)
1.4.8 Others
1.5 Market by Application
1.5.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Pharmacy And Drugstores
1.5.3 Hospital Pharmacy
1.5.4 Online Drug Stores
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Perspective (2015-2026)
2.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Growth Trends by Regions
2.2.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Market Size
3.1.1 Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Revenue (2015-2020)
3.1.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio
3.2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in 2019
3.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players Head office and Area Served
3.4 Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Solution and Service
3.5 Date of Enter into Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)
5.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
6.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in North America (2019-2020)
6.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
6.4 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
7.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in Europe (2019-2020)
7.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
7.4 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

8 China
8.1 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
8.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in China (2019-2020)
8.3 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
8.4 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
9.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in Japan (2019-2020)
9.3 Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
9.4 Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
10.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

11 India
11.1 India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
11.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in India (2019-2020)
11.3 India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
11.4 India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2015-2020)
12.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Taro
13.1.1 Taro Company Details
13.1.2 Taro Business Overview
13.1.3 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.1.4 Taro Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020))
13.1.5 Taro Recent Development
13.2 Oceanside Pharmaceuticals
13.2.1 Oceanside Pharmaceuticals Company Details
13.2.2 Oceanside Pharmaceuticals Business Overview
13.2.3 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.2.4 Oceanside Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.2.5 Oceanside Pharmaceuticals Recent Development
13.3 Pfizer
13.3.1 Pfizer Company Details
13.3.2 Pfizer Business Overview
13.3.3 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.3.4 Pfizer Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.3.5 Pfizer Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.4.4 Novartis Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 A-S Medication Solutions
13.5.1 A-S Medication Solutions Company Details
13.5.2 A-S Medication Solutions Business Overview
13.5.3 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.5.4 A-S Medication Solutions Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.5.5 A-S Medication Solutions Recent Development
13.6 Preferred Pharmaceuticals
13.6.1 Preferred Pharmaceuticals Company Details
13.6.2 Preferred Pharmaceuticals Business Overview
13.6.3 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.6.4 Preferred Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.6.5 Preferred Pharmaceuticals Recent Development
13.7 Syntex Pharmaceuticals
13.7.1 Syntex Pharmaceuticals Company Details
13.7.2 Syntex Pharmaceuticals Business Overview
13.7.3 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.7.4 Syntex Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.7.5 Syntex Pharmaceuticals Recent Development
13.8 Valeant Canada
13.8.1 Valeant Canada Company Details
13.8.2 Valeant Canada Business Overview
13.8.3 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.8.4 Valeant Canada Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.8.5 Valeant Canada Recent Development
13.9 Technilab Pharma
13.9.1 Technilab Pharma Company Details
13.9.2 Technilab Pharma Business Overview
13.9.3 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.9.4 Technilab Pharma Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.9.5 Technilab Pharma Recent Development
13.10 Allergan
13.10.1 Allergan Company Details
13.10.2 Allergan Business Overview
13.10.3 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
13.10.4 Allergan Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020)
13.10.5 Allergan Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue
Table 3. Ranking of Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Analgesics
Table 6. Key Players of Anti-Inflammatory And Anti-Edematous Agents
Table 7. Key Players of Antihistaminic
Table 8. Key Players of NSAIDs
Table 9. Key Players of Oral/Topical Glucocorticoids
Table 10. Key Players of Pyridoxine (Vitamin B6)
Table 11. Key Players of Others
Table 12. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Regions (2015-2020)
Table 16. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Growth Strategy
Table 22. Main Points Interviewed from Key Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players
Table 23. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Players (2015-2020) (Million US$)
Table 24. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Players (2015-2020)
Table 25. Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment as of 2019)
Table 26. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Solution and Service
Table 29. Date of Enter into Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 32. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Share by Type (2015-2020)
Table 33. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Type (2021-2026)
Table 34. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Share by Application (2015-2020)
Table 35. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 36. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Share by Application (2021-2026)
Table 37. North America Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 39. North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 40. North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 41. North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 42. North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 43. Europe Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 45. Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 47. Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 49. China Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 50. China Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 51. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 52. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 53. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 54. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 55. Japan Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 57. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 59. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 63. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 65. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 67. India Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 68. India Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 69. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 70. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 71. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 72. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share (2019-2020)
Table 75. Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2015-2020)
Table 77. Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2015-2020)
Table 79. Taro Company Details
Table 80. Taro Business Overview
Table 81. Taro Product
Table 82. Taro Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 83. Taro Recent Development
Table 84. Oceanside Pharmaceuticals Company Details
Table 85. Oceanside Pharmaceuticals Business Overview
Table 86. Oceanside Pharmaceuticals Product
Table 87. Oceanside Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 88. Oceanside Pharmaceuticals Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Novartis Company Details
Table 95. Novartis Business Overview
Table 96. Novartis Product
Table 97. Novartis Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 98. Novartis Recent Development
Table 99. A-S Medication Solutions Company Details
Table 100. A-S Medication Solutions Business Overview
Table 101. A-S Medication Solutions Product
Table 102. A-S Medication Solutions Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 103. A-S Medication Solutions Recent Development
Table 104. Preferred Pharmaceuticals Company Details
Table 105. Preferred Pharmaceuticals Business Overview
Table 106. Preferred Pharmaceuticals Product
Table 107. Preferred Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 108. Preferred Pharmaceuticals Recent Development
Table 109. Syntex Pharmaceuticals Company Details
Table 110. Syntex Pharmaceuticals Business Overview
Table 111. Syntex Pharmaceuticals Product
Table 112. Syntex Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 113. Syntex Pharmaceuticals Recent Development
Table 114. Valeant Canada Business Overview
Table 115. Valeant Canada Product
Table 116. Valeant Canada Company Details
Table 117. Valeant Canada Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 118. Valeant Canada Recent Development
Table 119. Technilab Pharma Company Details
Table 120. Technilab Pharma Business Overview
Table 121. Technilab Pharma Product
Table 122. Technilab Pharma Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 123. Technilab Pharma Recent Development
Table 124. Allergan Company Details
Table 125. Allergan Business Overview
Table 126. Allergan Product
Table 127. Allergan Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2015-2020) (Million US$)
Table 128. Allergan Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Analgesics Features
Figure 3. Anti-Inflammatory And Anti-Edematous Agents Features
Figure 4. Antihistaminic Features
Figure 5. NSAIDs Features
Figure 6. Oral/Topical Glucocorticoids Features
Figure 7. Pyridoxine (Vitamin B6) Features
Figure 8. Others Features
Figure 9. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application: 2020 VS 2026
Figure 10. Pharmacy And Drugstores Case Studies
Figure 11. Hospital Pharmacy Case Studies
Figure 12. Online Drug Stores Case Studies
Figure 13. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Report Years Considered
Figure 14. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Regions: 2020 VS 2026
Figure 16. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Players in 2019
Figure 19. Global Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in 2019
Figure 21. North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed